Trastuzumab (T) plus oral vinorelbine (OV) in patients with advanced breast cancer (ABC) overexpressing Her2/neu

被引：0
|
作者：
不详
机构：
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：168 / 168
页数：1
相关论文
共 50 条
  • [21] Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer
    Baselga, J
    Tripathy, D
    Mendelsohn, J
    Baughman, S
    Benz, CC
    Dantis, L
    Sklarin, NT
    Seidman, AD
    Hudis, CA
    Moore, J
    Rosen, PP
    Twaddell, T
    Henderson, IC
    Norton, L
    SEMINARS IN ONCOLOGY, 1999, 26 (04) : 78 - 83
  • [22] ECONOMIC EVALUATION OF ADJUVANT TRASTUZUMAB IN THE TREATMENT OF EARLY, HER2/NEU-OVEREXPRESSING BREAST CANCER IN SINGAPORE
    Lopes, G. De Lima
    EJC SUPPLEMENTS, 2011, 9 (01): : 8 - 8
  • [23] Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
    Fiszman, Gabriel L.
    Jasnis, Maria A.
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2011, 2011
  • [24] Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer
    Morabito, Alessandro
    Longo, Raffaele
    Gattuso, Domenico
    Carillio, Guido
    Massaccesi, Cristian
    Mariani, Luigi
    Bonginelli, Paola
    Amici, Scolastica
    De Sio, Livia
    Fanelli, Massimo
    Torino, Francesco
    Bonsignori, Maurizio
    Gasparini, Giampietro
    ONCOLOGY REPORTS, 2006, 16 (02) : 393 - 398
  • [25] Trastuzumab plus intravenous or oral vinorelbine in chemonaive patients with HER-2 overexpressing metastatic breast cancer: Final results of an extended phase II trial
    Bernardo, Giovanni
    Palumbo, Raffaella
    Bernardo, Antonio
    Poggi, Guido
    Delmonte, Angelo
    Teragni, Cristina
    Frascaroli, Mara
    Jedrychowska, Ivona
    Canto, Andrea M.
    Strada, Maria Rosa
    ANNALS OF ONCOLOGY, 2006, 17 : 76 - 76
  • [26] Trastuzumab plus intravenous or oral vinorelbine in chemonaive patients with HER-2 overexpressing metastatic breast cancer - final results of an extended phase II trial
    Bernardo, G.
    Palumbo, R.
    Bernardo, A.
    Teragni, C.
    Poggi, G.
    Delmonte, A.
    Amatu, A.
    Frascaroli, M.
    Jedrychowska, I.
    Strada, M.
    EJC SUPPLEMENTS, 2008, 6 (07): : 175 - 175
  • [27] HER-2/neu determination in blood plasma of patients with HER2/neu overexpressing metastasized breast cancer:: A longitudinal study
    Hoopmann, M
    Neumann, R
    Tanasale, T
    Schöndorf, T
    ANTICANCER RESEARCH, 2003, 23 (2A) : 1031 - 1034
  • [28] HER2/neu expression in Venezuelan patients with locally advanced breast cancer
    Morales, Luisa
    Reigosa, Aldo
    Caleiras, Eduardo
    Mora, Richard
    Marrero, Nuria
    Payares, Eliecer
    Molina, Karla
    Sucre, Luis
    INVESTIGACION CLINICA, 2008, 49 (01): : 69 - 78
  • [29] Trastuzumab and oral vinorelbine (±endocrine therapy) as primary therapy in patients (pts) with HER-2/neu positive breast cancer.
    Torrisi, R.
    Magni, E.
    Dellapasqua, S.
    D'Alessandro, C.
    Veronesi, P.
    Luini, A.
    Minchella, I
    Ghisini, R.
    Nole, F.
    Viale, G.
    Goldhirsch, A.
    Colleoni, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S148 - S148
  • [30] HER2 overexpressing advanced breast cancer - a case report
    Dubianski, Roman
    Glogowska, Iwona
    ONCOLOGY IN CLINICAL PRACTICE, 2010, 6 (01): : 48 - 51
12345